New Data Underscoring Ability of Leapfrog Bio's OncoSLX Platform to Identify Drug Retargeting Opportunities for Treating Cancer Published in Nature Portfolio Journal

Study highlights importance of cancer driver biology in translating results from lab to patients -- -- Findings validate proprietary OncoSLX Platform (TM), a pharmacogenetic approach that captures the ...

New mutations in TP53 gene drive resistance to p53-targeted cancer therapy

Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for ...
The New England Journal of Medicine

Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3

Angiopoietin-like protein 3 (ANGPTL3) inhibits lipoprotein and endothelial lipases. ANGPTL3 loss-of-function genetic variants are associated with decreased levels of low-density lipoprotein ...
eLife

Separating selection from mutation in antibody language models

This important study introduces a new biology-informed strategy for deep learning models aiming to predict mutational effects in antibody sequences. It provides solid evidence that separating ...